Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01880086|
Recruitment Status : Active, not recruiting
First Posted : June 18, 2013
Results First Posted : June 5, 2017
Last Update Posted : June 5, 2017
The purpose of this randomized controlled clinical trial is to evaluate the effects of clomiphene citrate compared to placebo (substance without active medication) in men who are taking pain medication (opioids) for chronic pain conditions and who have low blood testosterone levels.
The condition of men having low testosterone with long-term pain medication (opioid) usage is called opioid-induced androgen deficiency (OPIAD). Low testosterone can be caused by pain medication effects on part of the brain (hypothalamic-pituitary axis) which ultimately result in decreased testosterone production by the testes. Typical symptoms of low testosterone (hypogonadism) may include decreased muscle mass, increased fat, osteoporosis, anemia, erectile dysfunction, delayed ejaculation. In addition, men with low testosterone may experience decreased attention, and decreased libido, fatigue, and depressed mood. Few studies have looked at hormonal changes caused by long-term opioid usage in men.
Clomiphene citrate, a selective estrogen receptor modulator (SERM) oral medication which inhibits estrogen effects (feedback) on the brain, has been identified by prior studies to raise testosterone in men with low testosterone (due to reasons other than chronic pain medication). Clomiphene citrate is also known to lead to increased sperm production in men with low testosterone unlike testosterone topical or injection medications. Although clomiphene citrate has been studied in hypogonadal men with beneficial outcomes and minimal side effects, no group has previously studied clomiphene citrate as treatment in patients with OPIAD.
|Condition or disease||Intervention/treatment||Phase|
|Hypogonadism Opioid-Related Disorders Male Infertility||Drug: Clomiphene citrate Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Clomiphene Citrate for the Treatment of Opioid-Induced Androgen Deficiency: Randomized Controlled Clinical Trial|
|Study Start Date :||August 2013|
|Actual Primary Completion Date :||June 2016|
|Estimated Study Completion Date :||June 2017|
Experimental: Clomiphene citrate
The initial dose of clomiphene citrate will be 25 mg (po, pill by mouth) every other day. This will be started at visit 2, week 0 of the study following diagnosis of low baseline testosterone (serum total testosterone <350 ng/dl in men <55 years, <300 ng/dl in men 55-65 years). Clomiphene citrate dose will be titrated up to a maximum of 50 mg daily according to serum total testosterone levels measured at follow-up visits during the 3 month duration of the study.
Drug: Clomiphene citrate
Placebo Comparator: Placebo
Placebo pill will be administered (po, pill by mouth) every other day starting at week 0 of the study in men diagnosed with low testosterone. Treatment will be delayed in these men until the 3 month completion of the study, at which time this group may also receive testosterone replacement therapy.
Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
Other Name: Sugar pill
- Serum Total Testosterone (Change From Baseline) [ Time Frame: 3 months post initial visit ]Morning venipuncture of serum total testosterone.
- Other Hormonal Profile (Change From Baseline) [ Time Frame: 3 months post initial visit ]Luteinizing hormone (LH)
- Androgen Deficiency in the Aging Male (ADAM) Questionnaire [ Time Frame: 3 months post initial visit ]Overall, study subjects will be assessed for possible change in hypogonadal, sexual function, and pain symptoms. Minimum score is 0 and maximum score is 10. 0 is most symptomatic, and 10 is least symptomatic.
- Hematocrit (%) [ Time Frame: 3 months post initial visit ]Measure hematocrit from baseline.
- Estradiol [ Time Frame: 3 months post initial visit ]
- Sexual Health Inventory for Men (SHIM) Questionnaire [ Time Frame: 3 months post initial visit ]Overall, study subjects will be assessed for possible change in hypogonadal, sexual function, and pain symptoms. Minimum score is 1, maximum score is 25. The minimum value is most symptomatic and maximum value is least symptomatic.
- Men's Sexual Health Questionnaire (MSHQ) Questionnaire [ Time Frame: 3 months post initial visit ]Overall, study subjects will be assessed for possible change in hypogonadal, sexual function, and pain symptoms. Minimum score is 1, maximum score is 20. Minimum score is considered most symptomatic, maximum score is considered least symptomatic.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01880086
|United States, New York|
|Weill Cornell Medical College, Department of Urology|
|New York, New York, United States, 10065|
|Principal Investigator:||Peter N Schlegel, MD||Weill Medical College of Cornell University|